EuroIntervention PCRonline - Connecting with the community


Standardising definitions for bioprosthetic structural valve deterioration and failure: the European avant-garde

1. London Health Sciences Centre, Western University, London, Ontario, Canada; 2. Keele Cardiovascular Research Group, Centre for Prognosis Research, Institute of Primary Care and Health Sciences, Keele University, Stoke-on-Trent, United Kingdom; 3. Centre for Heart Valve Innovation, St. Paul’s Hospital, University of British Columbia, Vancouver, BC, Canada


More than 15 years have passed since the first transcatheter aortic valve implantation (TAVI)1. Since then, transcatheter technology has evolved significantly and has become a standard therapy for patients considered at high2,3 or intermediate preoperative risk4,5 for surgical aortic valve replacement (SAVR). Notably, the most recent American guidelines for the management of patients with valvular heart disease placed a Class I recommendation for TAVI in prohibitive- and high-risk patients and a Class IIA recommendation for TAVI in intermediate-risk patients6.

As TAVI is increasingly considered in…

– OR –